Introduction
The JAK/STAT signaling pathway is involved in many cellular processes including development, differentiation and proliferation 1 . STAT transcription factors may induce or repress transcription and have been implicated in NK cell development and function [2] [3] [4] [5] [6] . STAT1 is known to regulate NK cell cytotoxicity and cytokine production 5, 7 . STAT4 is highly expressed in resting NK cells and regulates IFN-γ production upon IL-12 stimulation by activating the T-box transcription factor T-bet 8, 9 . STAT5 is essential for NK cell development and survival mediating IL-2 and IL-15 signaling 10 and STAT6 has been reported to be involved in the differentiation of NK cells 11 .
STAT3 is constitutively activated in many cancers and has been reported to mediate the crosstalk between tumor and immune cells 12, 13 . Cytokines produced by the tumor activate STAT3 in infiltrating immune cells and suppress their activity 13 . As a consequence NK cell functions may be altered -inhibitory as well as activating effects have been reported [2] [3] [4] .
Inhibiting STAT3 is a potential approach for the treatment of various forms of cancer. However, our knowledge of the role of STAT3 in NK cells is limited. Kortylewski and colleagues studied Mx1-Cre NK cells killed YAC-1 cells better, albeit only after prior B16F10 challenge 14 .
The complex interaction of the immune system does not allow any conclusion on the cellintrinsic role of STAT3 in NK cells.
To assess the role of STAT3 in NK cells we crossed Stat3 fl/fl with Ncr1-iCreTg mice 10, 15 . Ncr1-iCreTg mice with the consequences of global STAT3 loss.
Stat3

Material and Methods
Mice
Mice were bred on C57BL/6N background and maintained at the University of Veterinary
Medicine Vienna under pathogen-free conditions according to FELASA guidelines. Following mice were studied: Stat3
Mx1-Cre (inducible Cre expression in all cells that express the Mx1 promoter after type 1 interferon response, e.g. after Poly(I:C) injection, expressing one allele of the Cre-transgene) 16 , Stat3
Ncr1-iCreTg and Stat3 fl/fl littermates 15 , C57BL/6 mice expressing one allele of the Cre-transgene (Ncr1-iCreTg) 10 and wild-type littermates. All experiments were carried out with age-matched 6-12 week old mice and were approved by the institutional ethics committee and conform to Austrian law (license 66.009/0019-II/10b/2010 14.1.10 and 68.205/0218-II/3b/2012).
Cell culture
Splenic NK cells were isolated using DX5-labeled MACS ® beads according to the manufacturer's instructions (Miltenyi) and cultured with 5.000U/ml rhIL-2 (Proleukin ® , Novartis). NK cell stimulations were performed in the presence of 5.000U/ml rhIL-2 ± 5ng/ml rmIL-12 (R&D), 50ng/ml rmIL-15 (PeproTech), 100U/ml rmIFN-β (Sigma), 5ng/ml rmIL-10 (R&D), 100ng/ml rmIL-21 (Immunotools), 50ng/ml rmIL-23 (R&D), 100ng/ml rmIL-18 (R&D), 50ng/ml rmIL-6 (R&D) or 50ng/ml rmIL6Rα (R&D). Tumor cell lines were cultured as previously published 5 . Both v-abl + transformed cell lines used in this study were derived from C57BL6/N mice. 
Poly(I:C) treatment
NK cell cytotoxicity
In vitro cytotoxicity assays were performed as previously published 5, 17 . For the DNAM-1
blockade, NK cells were incubated with anti-CD226 for 1 hour at 4°C and washed. Blocking efficiency was checked by flow cytometry and the blocked cells were incubated with the tumor cells at different E:T ratios.
In vivo tumor challenge
For the B16F10 melanoma model, mice were injected i.v. with 5x10 4 B16F10 cells. After 24 days mice were sacrificed and lung tissue analyzed. Tumor nodules in the lung were counted by three independent researchers in a blinded manner. During the disease progression blood was analyzed by flow cytometry. For Kaplan-Meier plots, mice were sacrificed at the first signs of dyspnea and health detractions.
In the v-abl leukemic tumor model, 10 6 v-abl + tumor cells were injected i.v. or s.c. into each flank of the mice. After s.c. injection, mice were sacrificed at day 12 and tumor weight was determined. For the survival assay (i.v. injection), mice were sacrificed at first signs of paralysis and health detractions. During the disease progression the blood was analyzed by flow cytometry.
In the A-MuLV model newborn mice were injected with 100μL of replication-incompetent ecotropic retrovirus encoding for v-abl by i.p. injection as described previously 18 . Mice were checked daily for disease onset.
Western blotting
Preparation of protein lysates and western blot was done as previously reported 5 
Histology
Paraffin-embedded sections (3μm) were stained with Hematoxylin/Eosin according to standard histological procedures. Blood smears were fixated and stained using Hemacolor ® staining kit (Merck). All stainings were scanned and photographed with an Olympus IX71 microscope using CellSens Dimension Software (Olympus).
Statistical analysis
Unpaired t-test, Mann-Whitney (non-parametrical), one-way ANOVA with Tukey's post hoc test and log-rank tests were performed using GraphPad Prism ® Software version 5.0 (San Diego California USA) where appropriate. The level of significance is indicated for each experiment (* p < 0.05; ** p < 0.01; *** p < 0.001).
Results
NK cells develop and mature normally in the absence of Stat3
The numbers of NK cells in spleen and bone marrow were comparable in Stat3 before becoming fully mature (mNK) and migrating to the periphery 19 . NK cells at all stages of development (a gating scheme is presented in Figure 1B ) are present at comparable numbers in
Mx1-Cre animals we detected an increase in the NKP population, which does not translate to altered numbers of mature NK cells but most likely reflects changes in the cytokine milieu in the bone marrow of these animals ( Figure S1B ).
Q-PCR analysis verified the successful deletion and the significant decrease in levels of Stat3 mRNA ( Figure 1D ). While NK cells develop in the bone marrow, NK cell maturation occurs in the spleen. We failed to detect any significant changes in NK cell maturation in Stat3 
Increased levels of perforin and granzyme B in the absence or upon inhibition of STAT3
Levels of granzyme B protein and mRNA were investigated using freshly purified NK cells of ( Figure 5D ). No differences were observed in cytotoxicity assays using other target cell lines.
One major difference between target cell lines is the expression of the DNAM-1 ligand CD155, which is only found at high levels in B16F10 cells ( Figure 5E ). Blocking DNAM-1 using antibodies significantly reduced cytotoxicity and abolished the differences between Stat3
Ncr1-iCreTg and control cells ( Figure 5F ). Cytotoxicity against other target cell lines depends on other recognition receptors, activation of which ultimately leads to the release of granzymes and perforin. In vitro cytotoxicity assays employ NK cells expanded in IL-2 for a week. Western blot experiments showed that the changes in levels of perforin and granzyme B that we observe in freshly isolated NK cells lacking STAT3 are no longer detectable upon cultivation with IL-2 ( Figure S5E ) whereas the differences related to an increase in % DNAM-1 + cells persist ( Figure   S5F ).
Loss of STAT3 in NK cells improves tumor surveillance against leukemia
An increasing body of evidence describes control of leukemogenesis in an NK cell-dependent manner [29] [30] [31] suggested that altered granzyme B expression contributes to increased tumor cell surveillance 35, 36 . Interestingly, the amount of granzyme B protein was increased without a concomitant change in the level of mRNA, suggesting the involvement of microRNAs. Both perforin and granzyme B have been described as targets of microRNA-dependent regulation in NK cells [37] [38] [39] . Further research will be required to investigate whether STAT3 interferes with the control of microRNAs in NK cells.
In summary, our in vivo data define an inhibitory role for STAT3 in NK cell-dependent tumor surveillance. The evidence is compelling and unambiguous. The increase in cytolytic capacity involves more than one downstream molecular target; the increased expression levels of DNAM-1, perforin and granzyme B contribute to the effect. Our conclusions are based on several independent tumor models and it appears likely that they will be relevant to additional systems, including human cancers. The mechanism is still not fully understood and we cannot exclude the possibility that other mechanisms are involved. Further research is required to discover which molecular players contribute to the in vivo effects of deleting STAT3 in the NK cell compartment.
Our observations improve the prospects of patients suffering from cancer controlled by NK celldependent surveillance, such as many hematological diseases. Recent evidence has highlighted the contribution of NK cells to the control of minimal residual disease 40 . Although STAT3 has a dual role in tumor formation and acts both as a tumor suppressor and as a tumor promoter, in hematological malignancies it functions predominantly as tumor promoter. Mutations in STAT3
have been proposed to be drivers of hematological disorders 41, 42 
